The Ambient Light Multiple Myeloma Study
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. T...
Age: 21 years - 66+
Gender: All
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course
chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs,
such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX
...
Age: 18 years - 66+
Gender: All
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety,
tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination
with balstilimab or standard-of-care treatments in participants with refractory metastati...
Age: 18 years - 66+
Gender: All
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study is to test for any side effects from modakafusp alfa in
combination therapy and to determine the recommended dose of combination therapy with
modakafusp. The dose of modakafusp alfa will be increased a little at a time until the
highest...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in
participants with refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Age: 18 years - 66+
Gender: All
Phase 1b Combo w/ Ribociclib and Alpelisib
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are
as follows:
Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals
Corporation).
Treatment Group 2: OP-1250 in combination wi...
Age: 18 years - 66+
Gender: All
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune check...
Age: 18 years - 66+
Gender: All
Phase 2 Study of DKN-01 in Colorectal Cancer
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to
evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of
care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanc...
Age: 18 years - 66+
Gender: All
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
The primary objective of this prospective observational study is to characterize the gut and
oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients
and correlate these findings with cancer type, treatment efficacy and toxicity.
Age: 18 years - 66+
Gender: All
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
This study is open to people with newly diagnosed colorectal cancer. People who are scheduled
for surgery can participate. People either get a medicine called BI 765063 combined with
ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. ...
Age: 18 years - 66+
Gender: All
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
This phase III trial compares the addition of stereotactic radiosurgery before or after
surgery in treating patients with cancer that has spread to the brain (brain metastases).
Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of
...
Age: 18 years - 66+
Gender: All
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and
efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
Age: 18 years - 66+
Gender: All
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in
participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Age: 18 years - 66+
Gender: Male
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in
patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to
other places in the body (metastatic), or cannot be removed by surgery (unresectable).
...
Age: 18 years - 66+
Gender: All
Pembrolizumab in MIBC
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT...
Age: 18 years - 66+
Gender: All
A Multi Center Study of Sexual Toxicities After Radiotherapy
The purpose of this research is to understand how radiotherapy and other cancer treatments
impact sexual function in female cancer patients and to try to answer a question about why
some patients who receive radiotherapy are more likely to have side effects than oth...
Age: 18 years - 66+
Gender: Female
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel
out-of-specification (OOS).
Age: 18 years - 66+
Gender: All
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Age: 18 years - 66+
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug
conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once
every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovari...
Age: 18 years - 66+
Gender: Female